Video

Lani Alison: How Providers Discuss the OCM With Patients

Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, discusses how providers discuss the Oncology Care Model (OCM) with patients and the questions they ask about it.

Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates, discusses how providers discuss the Oncology Care Model (OCM) with patients and the questions they ask about it.

Transcript

How do providers discuss the concept of the OCM with patients, and what questions do patients ask about it?

One of the requirements of the OCM, or Oncology Care Model, is to make sure the patients receive what they call the beneficiary letters. The beneficiary letter is actually a letter to the patient who has qualified to be eligible for the Oncology Care Model patient care. When the patients actually receive this—either in the mail, or most of our practices actually give it during their visit and they say you’re now a member of this—they always ask, “What is this?” and “Am I going to pay extra for this?” And then now they understand they’re actually getting more and that this is a benefit from Medicare and they are like, “Medicare is giving me more? How much is this going to cost in my premiums?” No ma’am or sir, this isn’t going to cost you anything.

Those are really most of the questions that we get: whether the co-pay is going to go up, whether they’re going to get a raise in their premiums, and what are those benefits that they are not getting now that this particular service is going to offer them. Those are most of the questions we get about OCM.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo